89bio drops 2%, prices $125M stock offering

seekingalpha11-13

Clinical-stage biopharmaceutical company 89bio (NASDAQ:ETNB) priced its previously announced upsized underwritten public offering of 11.46M shares at a price per share of $8.50 and pre-funded warrants...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483902577?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-13 14:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483902577","market":"fut","top_or_hot":-1,"title":"89bio drops 2%, prices $125M stock offering","media":"seekingalpha","content":"<div>\n<p>Clinical-stage biopharmaceutical company 89bio (NASDAQ:ETNB) priced its previously announced upsized underwritten public offering of 11.46M shares at a price per share of $8.50 and pre-funded warrants...</p>\n\n<a href=\"https://seekingalpha.com/news/4283481-89bio-drops-2-prices-125m-stock-offering\">Source Link</a>\n\n</div>\n","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>89bio drops 2%, prices $125M stock offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n89bio drops 2%, prices $125M stock offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 14:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4283481-89bio-drops-2-prices-125m-stock-offering><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Clinical-stage biopharmaceutical company 89bio (NASDAQ:ETNB) priced its previously announced upsized underwritten public offering of 11.46M shares at a price per share of $8.50 and pre-funded warrants...</p>\n\n<a href=\"https://seekingalpha.com/news/4283481-89bio-drops-2-prices-125m-stock-offering\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ETNB","symbol_name":"89Bio, Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/4283481-89bio-drops-2-prices-125m-stock-offering","article_id":"2483902577","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483902577","pubTimestamp":1731479331,"columns":[],"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"Clinical-stage biopharmaceutical company 89bio (NASDAQ:ETNB) priced its previously announced upsized underwritten public offering of 11.46M shares at a price per share of $8.50 and pre-funded warrants to purchase up to 3.25M shares at a public offering price of $8.499.  Underwriters have","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ETNB":"89Bio, Inc.","TQQQ":"纳指三倍做多ETF","BK4139":"生物科技","QID":"纳指两倍做空ETF","SQQQ":"纳指三倍做空ETF",".IXIC":"NASDAQ Composite","PSQ":"纳指反向ETF","BK4585":"ETF&股票定投概念","QLD":"纳指两倍做多ETF"},"translate_title":"89bio股价下跌2%，发行价格为1.25亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ETNB":0.9,".IXIC":0.76,"MNQmain":0.6,"NQmain":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"Clinical-stage biopharmaceutical company 89bio (NASDAQ:ETNB) priced its previously announced upsized underwritten public offering of 11.46M shares at a price per share of $8.50 and pre-funded warrants to purchase up to 3.25M shares at a public offering price of $8.499.  Underwriters have","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483902577"}